实用老年医学

实用老年医学 ›› 2023, Vol. 37 ›› Issue (11): 1107-1110.doi: 10.3969/j.issn.1003-9198.2023.11.007

• 临床研究 • 上一篇    下一篇

卡瑞利珠单抗联合化疗治疗老年晚期食管鳞癌疗效分析

邱天竹, 许有涛, 李晓林, 张皓   

  1. 210029 江苏省南京市,南京医科大学第一附属医院肿瘤科(邱天竹,张皓); 老年消化科(李晓林);
    210009 江苏省南京市,江苏省肿瘤医院江苏省肿瘤防治研究所(南京医科大学附属肿瘤医院)江苏省恶性肿瘤分子生物学及转化医学重点实验室(许有涛)
  • 收稿日期:2022-12-27 出版日期:2023-11-20 发布日期:2023-11-22
  • 通讯作者: 张皓,Email: dndxzh@njmu.edu.cn
  • 基金资助:
    国家自然科学基金资助项目(81871942);江苏省重大疾病生物资源样本库肺癌子库开放课题(SBK202004005)

Efficacy of camrelizumab plus chemotherapy for advanced esophageal squamous cell carcinoma in the elderly

QIU Tian-zhu, XU You-tao, LI Xiao-lin, ZHANG Hao   

  1. Department of Oncology(QIU Tian-zhu, ZHANG Hao); Department of Geriatrics (LI Xiao-lin), the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China;
    Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Cancer Hospital (the Affiliated Cancer Hospital of Nanjing Medical University), Nanjing 210009, China (XU You-tao)
  • Received:2022-12-27 Online:2023-11-20 Published:2023-11-22
  • Contact: ZHANG Hao, Email: dndxzh@njmu.edu.cn

PDF (PC)

569

摘要： 目的 探讨程序性死亡受体-1(PD-1)抑制剂卡瑞利珠单抗联合紫杉醇和奈达铂对老年晚期食管鳞癌病人疗效的影响。 方法 将我院2020年1月至2021年1月期间收治的60例老年晚期食管癌病人分为单纯化疗组(紫杉醇联合奈达铂)30例,卡瑞利珠单抗联合化疗组(卡瑞利珠单抗联合紫杉醇和奈达铂)30例,对比2组疗效、T淋巴细胞亚群及不良反应。 结果 卡瑞利珠单抗联合化疗组的疾病控制率高于单纯化疗组(83.3% 比60.0%,P＜0.05),但2组T淋巴细胞亚群水平差异无统计学意义(P>0.05)。卡瑞利珠单抗联合化疗组最常见的不良反应依次为贫血、毛细血管瘤和白细胞减少;单纯化疗组最常见的不良反应依次为贫血、白细胞减少和呕吐。 结论 老年晚期食管癌病人在化疗基础上联合PD-1 抑制剂卡瑞利珠单抗治疗,可提高疾病控制率,且安全性良好,可在临床推广。

关键词: 晚期食管鳞癌, 疗效, 安全性, 卡瑞利珠单抗, 紫杉醇, 奈达铂, T 淋巴细胞亚群

Abstract: Objective To investigate the efficacy of programmed cell death protein 1(PD-1)inhibitor combined with paclitaxel and nedaplatin in the first line therapy for advanced esophageal squamous cell carcinoma(ESCC)in the elderly. Methods A total of 60 elderly patients with ESCC admitted to our hospital from January 2020 to January 2021 were enrolled and divided into the chemotherapy group(paclitaxel and nedaplatin) and the immunotherapy group(camrelizumab combined with paclitaxel and nedaplatin), with 30 cases in each group. The efficacy, T-lymphocyte subsets, and adverse reactions of the two groups were observed and compared. Results The disease control rate in the immunotherapy group was significantly higher than that in the chemotherapy group (83.3% vs 60.0%,P＜0.05). There were no statistically significant differences in the levels of T-lymphocyte subsets between the two groups. The most common adverse reactions in immunotherapy group were anemia, reactive capillary hyperplasia and leukopenia, compared with anemia, leukopenia and vomit in chemotherapy group. Conclusions The combination of camrelizumab monotherapy with chemotherapy can improve the disease control rate with good safety in the elderly patients with advanced ESCC, which can be promoted in clinical practice.

Key words: advanced esophageal squamous cell carcinoma, efficacy, safety, camrelizumab, paclitaxel, nedaplatin, T-lymphocyte subsets

中图分类号: